A Phase 1, First-in-human Study of VX-634

Clinical trial NCT05579431 · COMPLETED

Trial details

NCT number: NCT05579431
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Alpha 1-Antitrypsin Deficiency

Start date: 2022-10-13
Primary completion: 2023-05-24
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.